Glaxosmithkline Plc Adr Stock Performance
| GSK Stock | USD 60.87 1.94 3.29% |
On a scale of 0 to 100, GlaxoSmithKline PLC holds a performance score of 22. The company retains a Market Volatility (i.e., Beta) of 0.54, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, GlaxoSmithKline PLC's returns are expected to increase less than the market. However, during the bear market, the loss of holding GlaxoSmithKline PLC is expected to be smaller as well. Please check GlaxoSmithKline PLC's coefficient of variation, semi variance, period momentum indicator, as well as the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether GlaxoSmithKline PLC's current trending patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in GlaxoSmithKline PLC ADR are ranked lower than 22 (%) of all global equities and portfolios over the last 90 days. Despite quite weak basic indicators, GlaxoSmithKline PLC disclosed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.29 | Five Day Return 4.18 | Year To Date Return 22.65 | Ten Year Return 54.49 | All Time Return 9.2 K |
Forward Dividend Yield 0.0303 | Payout Ratio | Last Split Factor 1226:1000 | Forward Dividend Rate 1.78 | Dividend Date 2026-04-09 |
1 | 9 more drugmakers agree to Trumps policy to lower some prices | 12/19/2025 |
2 | TPG closes in on 1bn-plus deal for GP patient records system supplier | 01/06/2026 |
| GlaxoSmithKline PLC dividend paid on 8th of January 2026 | 01/08/2026 |
3 | FDA commissioners drug review plan sparks alarm | 01/16/2026 |
4 | GSK Reports Next Week Wall Street Expects Earnings Growth | 01/28/2026 |
5 | BioIVT Appoints Dr. Auro Nair as Chief Executive Officer | 02/02/2026 |
6 | GSK Surpasses Q4 Earnings and Revenue Estimates | 02/04/2026 |
7 | GSK shares uptick for seven consecutive sessions | 02/06/2026 |
8 | GlaxoSmithKline Pharmaceuticals Limiteds market cap surged 32b last week, public companies who have a lot riding on the company were rewarded | 02/11/2026 |
9 | Mark Hillmans Strategic Move Significant Addition to State Street SPDR SP 500 ETF Trust | 02/17/2026 |
| Begin Period Cash Flow | 3.6 B | |
| Total Cashflows From Investing Activities | -5.7 B |
GlaxoSmithKline | Build AI portfolio with GlaxoSmithKline Stock |
GlaxoSmithKline PLC Relative Risk vs. Return Landscape
If you would invest 4,634 in GlaxoSmithKline PLC ADR on November 19, 2025 and sell it today you would earn a total of 1,453 from holding GlaxoSmithKline PLC ADR or generate 31.36% return on investment over 90 days. GlaxoSmithKline PLC ADR is generating 0.4611% of daily returns assuming volatility of 1.6388% on return distribution over 90 days investment horizon. In other words, 14% of stocks are less volatile than GlaxoSmithKline, and above 91% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
GlaxoSmithKline PLC Target Price Odds to finish over Current Price
The tendency of GlaxoSmithKline Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 60.87 | 90 days | 60.87 | near 1 |
Based on a normal probability distribution, the odds of GlaxoSmithKline PLC to move above the current price in 90 days from now is near 1 (This GlaxoSmithKline PLC ADR probability density function shows the probability of GlaxoSmithKline Stock to fall within a particular range of prices over 90 days) .
GlaxoSmithKline PLC Price Density |
| Price |
Predictive Modules for GlaxoSmithKline PLC
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as GlaxoSmithKline PLC ADR. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of GlaxoSmithKline PLC's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
GlaxoSmithKline PLC Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. GlaxoSmithKline PLC is not an exception. The market had few large corrections towards the GlaxoSmithKline PLC's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold GlaxoSmithKline PLC ADR, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of GlaxoSmithKline PLC within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.34 | |
β | Beta against Dow Jones | 0.54 | |
σ | Overall volatility | 3.76 | |
Ir | Information ratio | 0.20 |
GlaxoSmithKline PLC Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of GlaxoSmithKline PLC for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for GlaxoSmithKline PLC ADR can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| GlaxoSmithKline PLC has a strong financial position based on the latest SEC filings | |
| On 8th of January 2026 GlaxoSmithKline PLC paid $ 0.4096 per share dividend to its current shareholders | |
| Latest headline from finance.yahoo.com: Mark Hillmans Strategic Move Significant Addition to State Street SPDR SP 500 ETF Trust |
GlaxoSmithKline PLC Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of GlaxoSmithKline Stock often depends not only on the future outlook of the current and potential GlaxoSmithKline PLC's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. GlaxoSmithKline PLC's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 2.1 B | |
| Cash And Short Term Investments | 3.4 B |
GlaxoSmithKline PLC Fundamentals Growth
GlaxoSmithKline Stock prices reflect investors' perceptions of the future prospects and financial health of GlaxoSmithKline PLC, and GlaxoSmithKline PLC fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on GlaxoSmithKline Stock performance.
| Return On Equity | 0.43 | ||||
| Return On Asset | 0.0978 | ||||
| Profit Margin | 0.17 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 137.81 B | ||||
| Shares Outstanding | 2.01 B | ||||
| Price To Earning | 11.80 X | ||||
| Price To Book | 5.30 X | ||||
| Price To Sales | 3.62 X | ||||
| Revenue | 31.95 B | ||||
| Gross Profit | 23.72 B | ||||
| EBITDA | 11.62 B | ||||
| Net Income | 5.59 B | ||||
| Cash And Equivalents | 2.75 B | ||||
| Cash Per Share | 0.32 X | ||||
| Total Debt | 17.69 B | ||||
| Debt To Equity | 0.98 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 5.57 X | ||||
| Cash Flow From Operations | 7.14 B | ||||
| Earnings Per Share | 3.78 X | ||||
| Market Capitalization | 118.25 B | ||||
| Total Asset | 61.01 B | ||||
| Retained Earnings | 10.19 B | ||||
| Working Capital | (4.7 B) | ||||
| Current Asset | 16.59 B | ||||
| Current Liabilities | 13.42 B | ||||
About GlaxoSmithKline PLC Performance
By examining GlaxoSmithKline PLC's fundamental ratios, stakeholders can obtain critical insights into GlaxoSmithKline PLC's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that GlaxoSmithKline PLC is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 241.08 | 161.50 | |
| Return On Tangible Assets | 0.15 | 0.19 | |
| Return On Capital Employed | 0.18 | 0.17 | |
| Return On Assets | 0.09 | 0.15 | |
| Return On Equity | 0.35 | 0.50 |
Things to note about GlaxoSmithKline PLC ADR performance evaluation
Checking the ongoing alerts about GlaxoSmithKline PLC for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for GlaxoSmithKline PLC ADR help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| GlaxoSmithKline PLC has a strong financial position based on the latest SEC filings | |
| On 8th of January 2026 GlaxoSmithKline PLC paid $ 0.4096 per share dividend to its current shareholders | |
| Latest headline from finance.yahoo.com: Mark Hillmans Strategic Move Significant Addition to State Street SPDR SP 500 ETF Trust |
- Analyzing GlaxoSmithKline PLC's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether GlaxoSmithKline PLC's stock is overvalued or undervalued compared to its peers.
- Examining GlaxoSmithKline PLC's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating GlaxoSmithKline PLC's management team can have a significant impact on its success or failure. Reviewing the track record and experience of GlaxoSmithKline PLC's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of GlaxoSmithKline PLC's stock. These opinions can provide insight into GlaxoSmithKline PLC's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. Market participants price GlaxoSmithKline higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive GlaxoSmithKline PLC assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.551 | Dividend Share 0.66 | Earnings Share 3.78 | Revenue Per Share | Quarterly Revenue Growth 0.062 |
Investors evaluate GlaxoSmithKline PLC ADR using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating GlaxoSmithKline PLC's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause GlaxoSmithKline PLC's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, GlaxoSmithKline PLC's market price signifies the transaction level at which participants voluntarily complete trades.